1. Pink Sheet

FDA Guidance Addresses Self-Identification, Facility Payments Under GDUFA

 
• By Joanne S. Eglovitch

An FDA guidance addresses which types of facilities must self-report under GDUFA and pay the facility fee and which facilities must just self-report. Guide also covers whether two separate locations of the same company have to pay a user fee.

FDA issued guidance in a question-and-answer format on July 25 that addresses which types of generic drug manufacturers must self-report under the Generic Drug User Fee Act and pay facility fees, and which facilities need only self-report. The guidance also addresses what is considered a “fatal flaw” that can terminate inspections of generic drug facilities.

The document is titled “Generic Drug User Fee Amendments of 2012: Questions and Answers Related to Self-Identification of Facilities, Review...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Pink Sheet

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 
• By Neena Brizmohun

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

Global Pharma Guidance Tracker - June 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

US FDA’s CRL Release More Incremental Than ‘Radical’ Transparency

 
• By Bridget Silverman

The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.